Evidence map›Paper›PMID 37081963›Full record

ArticleFrontiers in pharmacology2023

LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA

Guoying Cao, Jingjing Wang, Jinjie He, Yingying Hu, Haijing Yang, Linling Que, Xianghong Gu, Jicheng Yu, Xiaojie Wu, Jufang Wu and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Guoying CaoPhase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, China.
Jingjing WangPhase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, China.
Jinjie HePhase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, China.
Yingying HuPhase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, China.
Haijing YangPhase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, China.
Linling QueDrug Clinical Trial Institution, The Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, China.
Xianghong GuDrug Clinical Trial Institution, The Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, China.
Jicheng YuPhase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, China.
Xiaojie WuPhase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, China.
Jufang WuPhase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, China.
Wei FangLivzon Mabpharm Inc., Zhu Hai, Guangdong, China.
Qing HeDrug Clinical Trial Institution, The Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, China.
Jing ZhangPhase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, China.
Fudan University · CNHuashan Hospital · CNWuxi People's Hospital · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biosimilarimmunogenicitypharmacokineticssafetytocilizumab

Identifiers

PMID37081963
PMCPMC10110837
OpenAlexW4362566800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.